GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
4
Ucap Cloud Information Technology Co.,Ltd
688228
5
Yangtze Optical Electronic
688143
CN Stock MarketDetailed Quotes
000919 Jinling Pharmaceutical
- 6.50
- -0.01-0.15%
Market Closed Jan 24 15:00 CST
4.05BMarket Cap55.08P/E (TTM)
6.51High6.40Low61.58KlotVolume6.50Open6.51Pre Close39.81MTurnover1.04%Turnover Ratio40.63P/E (Static)623.71MShares7.8552wk High1.07P/B3.84BFloat Cap5.2852wk Low7.16Limit Up590.36MShs Float29.05Historical High5.86Limit Down1.69%Amplitude0.09Historical Low0.10Dividend TTM6.46Avg Price36.40KlotAsk1.54%Div YieldTTM100Lot Size24.35KlotBid
Jinling Pharmaceutical News
Jinling Pharmaceutical: Jinling Pharmaceutical Co., Ltd. 2024 Annual Performance Forecast
Jinling Pharmaceutical (000919.SZ): The subsidiary involved in Retirement business currently mainly adopts the Institutions Retirement Operation model.
On January 8, Gelonghui reported that Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform that its subsidiary, which is involved in Retirement Business, mainly adopts an Institutional Retirement model for Operation. The Hefei Jinling Tianyi Smart Retirement project under construction plans to utilize a smart health retirement model to provide customers with intelligent elderly living, smart health management, intelligent Leisure experiences, and other retirement and rehabilitation services. It also plans to offer home-based retirement services in accordance with national policies and market-oriented Operation models.
Jinling Pharmaceutical (000919.SZ): Currently collaborating on technical Business with Nanjing University, China Pharmaceutical University, and other institutions.
On January 6th, Gelonghui reported that Jinling Pharmaceutical (000919.SZ) indicated in their investor interaction platform that the company is currently collaborating with Nanjing University, China Pharmaceutical University, and other institutions on technology and business.
Jinling Pharmaceutical (000919.SZ): No related technology or research on Brain-computer Interface.
On December 26, Gelonghui reported that Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform that the company has no Brain-computer Interface related technology or research.
Market Is Not Liking Jinling Pharmaceutical's (SZSE:000919) Earnings Decline as Stock Retreats 11% This Week
Jinling Pharmaceutical (000919.SZ): Magnesium sulfate injection has been approved for registration.
On December 11, 2023, Gelonghui reported that Jinling Pharmaceutical (000919.SZ) announced that its subsidiary, Nanjing Jinling Pharmaceutical Factory, received a "Pharmaceutical Registration Certificate" for magnesium sulfate injection issued by the National Medical Products Administration (Notification Number: 2024S30151). Magnesium sulfate injection can be used as an anticonvulsant for pregnancy-induced hypertension, to lower blood pressure, and to treat preeclampsia and eclampsia. Magnesium sulfate plays an important role in the prevention and treatment of eclampsia, hypertensive crises, asthma, and other diseases. Currently, China's "Guidelines for the Diagnosis and Treatment of Hypertensive Disorders in Pregnancy (2020)" ...
Jinling Pharmaceutical Completes Cancellation of Subsidiary
Jinling Pharmaceutical: Report for the third quarter of 2024
Jinling Pharmaceutical (000919.SZ): Intends to acquire a portion of shares of Xingong Fund and equity of non-cash distribution of Xingong Fund.
GeLongHui October 21st 丨 Jinling Pharmaceutical (000919.SZ) announced that, to build the company's global strategy of "medical and health care dual platform", improve the company's medical regional market layout, and at the same time resolve the same industry competition between Nanjing New Work Investment Group Co., Ltd. (referred to as "New Work Group") controlling Nanjing Meishan Hospital Co., Ltd. (referred to as "Nanjing Meishan Hospital") and the company, the company plans to acquire 164.7317 million yuan held by New Work Group South New Work Medical Industry Investment Fund Partnership Enterprise (Limited Partnership) (referred to as "Fund" or "New Work Fund") 28.46% of the contribution.
Unpleasant Surprises Could Be In Store For Jinling Pharmaceutical Company Limited's (SZSE:000919) Shares
The One-year Earnings Decline Is Not Helping Jinling Pharmaceutical's (SZSE:000919 Share Price, as Stock Falls Another 9.0% in Past Week
Jinling Pharmaceutical: 2024 Semi-Annual Report Summary
Jinling Pharmaceutical: Semi-Annual Report 2024
Jinling Pharmaceutical (000919.SZ) released its performance for the first half of the year, with a net income of 51.8188 million yuan, a decrease of 33.16%.
Jinling Pharmaceutical (000919.SZ) released its 2024 interim report. During the reporting period, the company achieved revenue...
Jinling Pharmaceutical (000919.SZ): The net income in the first half of the year was 51.8188 million yuan, a year-on-year decrease of 33.16%.
Jinling Pharmaceutical (000919.SZ) announced its semi-annual report for 2024, with revenue of 1.511 billion yuan, a year-on-year increase of 4.83%; net income attributable to shareholders of listed company was 51.8188 million yuan, a year-on-year decrease of 33.16%; net income attributable to shareholders of listed company after deducting non-recurring gains and losses was 45.2629 million yuan, a year-on-year decrease of 36.04%; basic earnings per share was 0.0913 yuan.
Jinling Pharmaceutical (000919.SZ): As of July 31st, the total number of shareholders in the company is 36,202.
Jinling Pharmaceutical (000919.SZ) stated on its investor interaction platform on August 1st that as of July 31st, 2024, the total number of shareholders in the company is 36,202.
Jinling Pharmaceutical (000919.SZ): As of July 19, the total number of shareholders of the company is 36,049.
Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform on July 25 that as of July 19, 2024, the total number of shareholders in the company was 36,049.
Jinling Pharmaceutical (000919.SZ): As of July 10, the total number of shareholders in the company is 36,316.
Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform of their website today, July 15th, that as of July 10th, 2024, the total number of shareholders in the company was 36,316.
Jinling Pharmaceutical (000919.SZ): Compound sulfamethoxazole injection passed the generic drug consistency evaluation.
On July 8th, Gelonhui reported that Jinling Pharmaceutical (000919.SZ) announced that its subsidiary, Nanjing Jinling Pharmaceutical Factory (hereinafter referred to as "Jinling Pharmaceutical Factory"), received the "Drug Supplement Application Approval Notification" (Notification No.: 2024B03021) issued and approved by the National Medical Products Administration (hereinafter referred to as "NMPA"), approving the approval of compound sulfamethoxazole injection through generic drug quality and efficacy consistency evaluation (hereinafter referred to as "generic drug consistency evaluation"). The indications for the company's compound sulfamethoxazole injection are: 1. For the treatment of adults and...
Jinling Pharmaceutical (000919.SZ): Its subsidiary, Ipratropium Bromide, has obtained a notice of approval for the marketing application of chemical raw materials.
On June 28, Gelunhui reported that Jinling Pharmaceutical (000919.SZ) recently announced that its subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as 'Dongsheng Pharmaceutical'), controlled by Jinling Pharmaceutical Co., Ltd., received the 'Chemical Active Pharmaceutical Ingredient Market Approval Notice' (Notice No. 2024YS00595) issued by the State Drug Administration for its ingredient of ipratropium bromide. Ipratropium bromide is used to relieve bronchospasm and asthma symptoms caused by chronic obstructive pulmonary disease (COPD), and is suitable for the prevention and treatment of asthma, especially for those who cannot tolerate such drugs due to the side effects of beta receptor agonists, such as muscle tremors and tachycardia.